Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR1 | O14842 | 1/20 | 0.55 |
| ▸ | LTB4R | Q15722 | 5/20 | 0.50 |
| ▸ | LTB4R2 | Q9NPC1 | 5/20 | 0.50 |
| ▸ | PTGES | O14684 | 2/20 | 0.49 |
| ▸ | AOC3 | Q16853 | 1/20 | 0.45 |
| ▸ | RAB9A | P51151 | 1/20 | 0.44 |
| ▸ | NPY5R | Q15761 | 1/20 | 0.44 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.44 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.44 |
| ▸ | LPAR1 | Q92633 | 1/20 | 0.43 |
| ▸ | LPAR5 | Q9H1C0 | 1/20 | 0.43 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.43 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.43 |
| ▸ | GPR52 | Q9Y2T5 | 1/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4176141 | 0.87 | CDK8 (0.51) | FFAR1LTB4RLTB4R2AOC3 | |
| SCHEMBL4186373 | 0.84 | FFAR1 (0.52) | FFAR1LTB4RLTB4R2PTGESRAB9A | |
| SCHEMBL4177596 | 0.83 | PTGES (0.47) | LTB4RLTB4R2PTGESAOC3NPSR1 | |
| SCHEMBL4174373 | 0.80 | FFAR1 (0.54) | FFAR1LTB4RLTB4R2PTGESNPSR1 | |
| SCHEMBL4189140 | 0.77 | NPSR1 (0.50) | FFAR1LTB4RLTB4R2AOC3NPY5R | |
| SCHEMBL4175962 | 0.77 | FFAR1 (0.56) | FFAR1PTGESRAB9AMTNR1AMTNR1B | |
| SCHEMBL4175597 | 0.76 | NPSR1 (0.40) | FFAR1LTB4RLTB4R2AOC3RAB9A | |
| SCHEMBL6771470 | 0.76 | FFAR1 (0.44) | FFAR1PTGESMTNR1AMTNR1B | |
| SCHEMBL7884371 | 0.74 | FFAR1 (0.57) | FFAR1PTGESRAB9A | |
| SCHEMBL4175735 | 0.74 | FFAR1 (0.41) | FFAR1LTB4RLTB4R2PTGESAOC3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090182020-A1 | SUBSTITUTED BIS(HETERO)AROMATIC N--ETHYLPROPIOLAMIDES AND USE THEREOF FOR PRODUCTION OF MEDICAMENTS | GRUNENTHAL GMBH (DE) | 2009-07-16 | — | — | US | claimed |
| EP-1968935-A1 | SUBSTITUTED BIS(HETERO)AROMATIC N-ETHYLPROPIOLAMIDES AND USE THEREOF FOR PRODUCTION OF MEDICAMENTS | Grünenthal GmbH (DE) | 2008-09-17 | — | — | EP | claimed |
| WO-2007079958-A1 | SUBSTITUTED BIS(HETERO)AROMATIC N-ETHYLPROPIOLAMIDES AND USE THEREOF FOR PRODUCTION OF MEDICAMENTS | Grünenthal GmbH (DE) | 2007-07-19 | — | — | WO | claimed |
| US-20090182020-A1 | SUBSTITUTED BIS(HETERO)AROMATIC N--ETHYLPROPIOLAMIDES AND USE THEREOF FOR PRODUCTION OF MEDICAMENTS | GRUNENTHAL GMBH (DE) | 2009-07-16 | — | — | US | disclosed |
| EP-1968935-A1 | SUBSTITUTED BIS(HETERO)AROMATIC N-ETHYLPROPIOLAMIDES AND USE THEREOF FOR PRODUCTION OF MEDICAMENTS | Grünenthal GmbH (DE) | 2008-09-17 | — | — | EP | disclosed |
| WO-2007079958-A1 | SUBSTITUTED BIS(HETERO)AROMATIC N-ETHYLPROPIOLAMIDES AND USE THEREOF FOR PRODUCTION OF MEDICAMENTS | Grünenthal GmbH (DE) | 2007-07-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090182020-A1 | SUBSTITUTED BIS(HETERO)AROMATIC N--ETHYLPROPIOLAMIDES AND USE THEREOF FOR PRODUCTION OF MEDICAMENTS | FHIT, CYP3A43, DNPEP | FFAR1 4316/4885LTB4R 3185/4885LTB4R2 2285/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.